An alternative approach to target GLP-1 is the identification of GLP-1 secretagogues that have the potential, either alone or in combination with DPP IV inhibitors to enhance circulating levels of bioactive GLP-1 in patients with T2DM [4]. This evidence concerns the gene GCG and type 2 diabetes mellitus.